Speech-Language Pathologists in Eaton, OH Accepting Medicare

7 Speech-Language Pathologists found. Showing 1 - 7

Michele Ann Gething, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 854 Oslo Cv, Eaton, OH 45320 Phone: 937-336-0369    Fax: 937-456-6507

Hannah Loughman, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 911 W Main St, Eaton, OH 45320 Phone: 937-456-6505

Mrs. Aimee Mclemore, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 597 Hillcrest Dr, Eaton, OH 45320 Phone: 937-456-1422

Kirsten Von Der Embse Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 597 Hillcrest Dr, Eaton, OH 45320 Phone: 937-456-1187

Samantha Ardle Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 814 Camden Rd, Eaton, OH 45320 Phone: 937-456-2286

Jeanne Current, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 550 Hallmark Dr, Reid Rehabilitation Services, Eaton, OH 45320 Phone: 765-983-3092    Fax: 765-983-3237

Robert Reyes Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 506b Aukerman St, Eaton, OH 45320 Phone: 937-456-3874

News Archive

GOP debate audience's reaction to treating uninsured sparks controversy

When presidential hopeful Rep. Ron Paul was asked if society should let an uninsured man who needs treatment die, some members of the audience cheered.

UIC researchers receive $10.15 million grant to develop treatment for dry eye conditions

Researchers at University of Illinois Chicago have been awarded a five-year, $10.15 million grant to develop a broad-spectrum immunomodulatory eye drop to treat patients with severe dry eye and ocular surface disease due to inflammatory and immune system disorders.

FDA, NIH awarded $53 million to create 14 Tobacco Centers of Regulatory Science

The U.S. Food and Drug Administration and the National Institutes of Health today, as part of an on-going interagency partnership, have awarded a total of up to $53 million to fund tobacco-related research in fiscal year 2013 to create 14 Tobacco Centers of Regulatory Science.

Merrimack commences MM-151 Phase 1 trial in refractory advanced solid tumors

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor.

High family medical bills appear to reduce use of expensive medications: Study

People with rheumatoid arthritis whose health insurance requires them to pay a higher share of the cost are less likely to use biotech drugs than those with coverage that is more generous. High family medical bills also appear to reduce the use of these powerful but expensive medications, according to a new study in Health Services Research.

Read more Medical News

› Verified 5 days ago